Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2015, Article ID 969182, 8 pages
http://dx.doi.org/10.1155/2015/969182
Review Article

An Overview of Diabetes Management in Schizophrenia Patients: Office Based Strategies for Primary Care Practitioners and Endocrinologists

1Departments of Psychiatry and Internal Medicine, Yale School of Medicine, 34 Park Street, New Haven, CT 06519, USA
2Department of Psychiatry, Yale School of Medicine, 34 Park Street, New Haven, CT 06519, USA

Received 5 January 2015; Revised 11 March 2015; Accepted 12 March 2015

Academic Editor: Kazuhiro Shiizaki

Copyright © 2015 Aniyizhai Annamalai and Cenk Tek. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Brown, “Excess mortality of schizophrenia. A meta-analysis,” The British Journal of Psychiatry, vol. 171, pp. 502–508, 1997. View at Publisher · View at Google Scholar · View at Scopus
  2. C. W. Colton and R. W. Manderscheid, “Congruencies in increased mortality rates, years of potential life lost, and causes of death among public mental health clients in eight states,” Preventing Chronic Disease, vol. 3, no. 2, article A42, 2006. View at Google Scholar · View at Scopus
  3. A. J. Mitchell, D. Vancampfort, K. Sweers, R. Van Winkel, W. Yu, and M. De Hert, “Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders—a systematic review and meta-analysis,” Schizophrenia Bulletin, vol. 39, no. 2, pp. 306–318, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. J. C. Ratliff, L. B. Palmese, E. L. Reutenauer, V. H. Srihari, and C. Tek, “Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness,” Psychosomatics, vol. 54, no. 1, pp. 67–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  5. C. G. Lyketsos, G. Dunn, M. J. Kaminsky, and W. R. Breakey, “Medical comorbidity in psychiatric inpatients relation to clinical outcomes and hospital length of stay,” Psychosomatics, vol. 43, no. 1, pp. 24–30, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. B. G. Druss, “Improving medical care for persons with serious mental illness: challenges and solutions,” The Journal of Clinical Psychiatry, vol. 68, supplement 4, pp. 40–44, 2007. View at Google Scholar · View at Scopus
  7. B. G. Druss, S. C. Marcus, J. Campbell et al., “Medical services for clients in community mental health centers: results from a national survey,” Psychiatric Services, vol. 59, no. 8, pp. 917–920, 2008. View at Publisher · View at Google Scholar · View at Scopus
  8. H. E. Lester, J. Q. Tritter, and H. Sorohan, “Patients' and health professionals' views on primary care for people with serious mental illness: focus group study,” The British Medical Journal, vol. 330, no. 7500, pp. 1122–1126, 2005. View at Publisher · View at Google Scholar · View at Scopus
  9. H. Verdoux, M. Tournier, and B. Bégaud, “Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies,” Acta Psychiatrica Scandinavica, vol. 121, no. 1, pp. 4–10, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. J. M. Meyer, V. G. Davis, D. C. Goff et al., “Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1,” Schizophrenia Research, vol. 101, no. 1–3, pp. 273–286, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. V. H. Srihari, V. H. Phutane, B. Ozkan et al., “Cardiovascular mortality in schizophrenia: defining a critical period for prevention,” Schizophrenia Research, vol. 146, no. 1–3, pp. 64–68, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. H. A. Nasrallah, J. M. Meyer, D. C. Goff et al., “Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline,” Schizophrenia Research, vol. 86, no. 1–3, pp. 15–22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Saha, D. Chant, and J. McGrath, “A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time?” Archives of General Psychiatry, vol. 64, no. 10, pp. 1123–1131, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. M. de Hert, V. Schreurs, D. Vancampfort, and R. van Winkel, “Metabolic syndrome in people with schizophrenia: a review,” World Psychiatry, vol. 8, no. 1, pp. 15–22, 2009. View at Google Scholar · View at Scopus
  15. M. de Hert, R. van Winkel, D. van Eyck et al., “Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study,” Clinical Practice and Epidemiology in Mental Health, vol. 2, article 14, 2006. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Kirkpatrick, B. J. Miller, C. Garcia-Rizo, E. Fernandez-Egea, and M. Bernardo, “Is abnormal glucose tolerance in antipsychotic-naïve patients with nonaffective psychosis confounded by poor health habits?” Schizophrenia Bulletin, vol. 38, no. 2, pp. 280–284, 2012. View at Publisher · View at Google Scholar · View at Scopus
  17. B. G. Druss and B. J. Mauer, “Health care reform and care at the behavioral health—Primary care interface,” Psychiatric Services, vol. 61, no. 11, pp. 1087–1092, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. F. Rouillon and F. Sorbara, “Schizophrenia and diabetes: epidemiological data,” European Psychiatry, vol. 20, supplement 4, pp. S345–S348, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. L. W. Harris, P. C. Guest, M. T. Wayland et al., “Schizophrenia: metabolic aspects of aetiology, diagnosis and future treatment strategies,” Psychoneuroendocrinology, vol. 38, no. 6, pp. 752–766, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. M. de Hert, V. Schreurs, K. Sweers et al., “Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review,” Schizophrenia Research, vol. 101, no. 1–3, pp. 295–303, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. J. Mitchell, D. Vancampfort, A. De Herdt, W. Yu, and M. De Hert, “Is the prevalence of metabolic syndrome and metabolic abnormalities increased in early schizophrenia? a comparative meta-analysis of first episode, untreated and treated patients,” Schizophrenia Bulletin, vol. 39, no. 2, pp. 295–305, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. S. Mukherjee, D. B. Schnur, and R. Reddy, “Family history of type 2 diabetes in schizophrenic patients,” The Lancet, vol. 1, no. 8636, article 495, 1989. View at Google Scholar · View at Scopus
  23. P. I. Lin and A. R. Shuldiner, “Rethinking the genetic basis for comorbidity of schizophrenia and type 2 diabetes,” Schizophrenia Research, vol. 123, no. 2-3, pp. 234–243, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Brenner, A. Liu, D. P. Laplante et al., “Cortisol response to a psychosocial stressor in schizophrenia: blunted, delayed, or normal?” Psychoneuroendocrinology, vol. 34, no. 6, pp. 859–868, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. S. Brown and E. S. Susser, “Prenatal nutritional deficiency and risk of adult schizophrenia,” Schizophrenia Bulletin, vol. 34, no. 6, pp. 1054–1063, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. McGrath, K. Saari, H. Hakko et al., “Vitamin D supplementation during the first year of life and risk of schizophrenia: a Finnish birth cohort study,” Schizophrenia Research, vol. 67, no. 2-3, pp. 237–245, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. R. C. Andrews, “Diabetes and schizophrenia: genes or zinc deficiency,” The Lancet, vol. 340, no. 8828, article 1160, 1992. View at Google Scholar · View at Scopus
  28. D. W. Haupt, “Differential metabolic effects of antipsychotic treatments,” European Neuropsychopharmacology, vol. 16, supplement 3, pp. S149–S155, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. I. C. Miron, V. C. Baroană, F. Popescu, and F. Ionică, “Pharmacological mechanisms underlying the association of antipsychotics with metabolic disorders,” Current Health Sciences Journal, vol. 40, no. 1, pp. 12–17, 2014. View at Publisher · View at Google Scholar
  30. J. C. Ratliff, L. B. Palmese, E. L. Reutenauer, E. Liskov, C. M. Grilo, and C. Tek, “The effect of dietary and physical activity pattern on metabolic profile in individuals with schizophrenia: a cross-sectional study,” Comprehensive Psychiatry, vol. 53, no. 7, pp. 1028–1033, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Brown, J. Birtwistle, L. Roe, and C. Thompson, “The unhealthy lifestyle of people with schizophrenia,” Psychological Medicine, vol. 29, no. 3, pp. 697–701, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Strassnig, J. S. Brar, and R. Ganguli, “Nutritional assessment of patients with schizophrenia: a preliminary study,” Schizophrenia Bulletin, vol. 29, no. 2, pp. 393–397, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. G. L. Daumit, R. W. Goldberg, C. Anthony et al., “Physical activity patterns in adults with severe mental illness,” The Journal of Nervous and Mental Disease, vol. 193, no. 10, pp. 641–646, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Dickerson, C. R. Stallings, A. E. Origoni et al., “Cigarette smoking among persons with schizophrenia or bipolar disorder in routine clinical settings, 1999–2011,” Psychiatric Services, vol. 64, no. 1, pp. 44–50, 2013. View at Google Scholar · View at Scopus
  35. G. L. Daumit, F. B. Dickerson, N.-Y. Wang et al., “A behavioral weight-loss intervention in persons with serious mental illness,” The New England Journal of Medicine, vol. 368, no. 17, pp. 1594–1602, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. C. A. Green, B. J. Yarborough, M. C. Leo et al., “The STRIDE weight loss and lifestyle intervention for individuals taking antipsychotic medications: a randomized trial,” The American Journal of Psychiatry, vol. 172, no. 1, pp. 71–81, 2015. View at Publisher · View at Google Scholar
  37. L. Chwastiak and C. Tek, “Management of obesity in the psychiatrist's office,” World Psychiatry, vol. 13, no. 2, pp. 193–195, 2014. View at Publisher · View at Google Scholar · View at Scopus
  38. J. M. Meyer and S. M. Stahl, “The metabolic syndrome and schizophrenia,” Acta Psychiatrica Scandinavica, vol. 119, no. 1, pp. 4–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. D. B. Allison, J. L. Mentore, M. Heo et al., “Antipsychotic-induced weight gain: a comprehensive research synthesis,” The American Journal of Psychiatry, vol. 156, no. 11, pp. 1686–1696, 1999. View at Google Scholar · View at Scopus
  40. L. Maayan, J. Vakhrusheva, and C. U. Correll, “Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysis,” Neuropsychopharmacology, vol. 35, no. 7, pp. 1520–1530, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. W. C. Knowler, E. Barrett-Connor, S. E. Fowler et al., “Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin,” The New England Journal of Medicine, vol. 346, no. 6, pp. 393–403, 2002. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Hasnain, S. K. Fredrickson, and W. V. R. Vieweg, “Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs,” Journal of Psychopharmacology, vol. 25, no. 6, pp. 715–721, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Y. Khan, M. MacAluso, R. J. McHale, M. M. Dahmen, K. Girrens, and F. Ali, “The adjunctive use of metformin to treat or prevent atypical antipsychotic-induced weight gain: a review,” Journal of Psychiatric Practice, vol. 16, no. 5, pp. 289–296, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. R.-R. Wu, J.-P. Zhao, X.-F. Guo et al., “Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: a double-blind, placebo-controlled study,” The American Journal of Psychiatry, vol. 165, no. 3, pp. 352–358, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. R.-R. Wu, J.-P. Zhao, H. Jin et al., “Lifestyle intervention and metformin for treatment of antipsychotic-induced weight gain: a randomized controlled trial,” The Journal of the American Medical Association, vol. 299, no. 2, pp. 185–193, 2008. View at Publisher · View at Google Scholar · View at Scopus
  46. E. Carrizo, V. Fernández, L. Connell et al., “Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study,” Schizophrenia Research, vol. 113, no. 1, pp. 19–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  47. J. M. Gierisch, J. A. Nieuwsma, D. W. Bradford et al., “Pharmacologic and behavioral interventions to improve cardiovascular risk factors in adults with serious mental illness: a systematic review and meta-analysis,” The Journal of Clinical Psychiatry, vol. 75, no. 5, pp. e424–e440, 2014. View at Publisher · View at Google Scholar · View at Scopus
  48. A. Annamalai, L. B. Palmese, L. A. Chwastiak, V. H. Srihari, and C. Tek, “High rates of obstructive sleep apnea symptoms among patients with schizophrenia,” Psychosomatics, vol. 56, no. 1, pp. 59–66, 2015. View at Publisher · View at Google Scholar
  49. M. Gitlin, “Lithium and the kidney: an updated review,” Drug Safety, vol. 20, no. 3, pp. 231–243, 1999. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Baptista, N. M. K. N. Y. Kin, and S. Beaulieu, “Treatment of the metabolic disturbances caused by antipsychotic drugs: focus on potential drug interactions,” Clinical Pharmacokinetics, vol. 43, no. 1, pp. 1–15, 2004. View at Publisher · View at Google Scholar · View at Scopus
  51. S. F. Ely, A. R. Neitzel, and J. R. Gill, “Fatal diabetic ketoacidosis and antipsychotic medication,” Journal of Forensic Sciences, vol. 58, no. 2, pp. 398–403, 2013. View at Publisher · View at Google Scholar · View at Scopus
  52. E.-H. Pok and W.-J. Lee, “Gastrointestinal metabolic surgery for the treatment of type 2 diabetes mellitus,” World Journal of Gastroenterology, vol. 20, no. 39, pp. 14315–14328, 2014. View at Publisher · View at Google Scholar
  53. W. C. Steinmann, K. Suttmoeller, R. Chitima-Matsiga, N. Nagam, N. R. Suttmoeller, and N. A. Halstenson, “Bariatric surgery: 1-year weight loss outcomes in patients with bipolar and other psychiatric disorders,” Obesity Surgery, vol. 21, no. 9, pp. 1323–1329, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. A. T. Ahmed, E. M. Warton, C. A. Schaefer, L. Shen, and R. S. Mcintyre, “The effect of bariatric surgery on psychiatric course among patients with bipolar disorder,” Bipolar Disorders, vol. 15, no. 7, pp. 753–763, 2013. View at Publisher · View at Google Scholar · View at Scopus